Показать сокращенную информацию
dc.contributor.author | Gamirova R. | |
dc.contributor.author | Shaimardanova R. | |
dc.contributor.author | Ziganshina L. | |
dc.date.accessioned | 2018-09-18T20:10:16Z | |
dc.date.available | 2018-09-18T20:10:16Z | |
dc.date.issued | 2012 | |
dc.identifier.issn | 0924-6479 | |
dc.identifier.uri | https://dspace.kpfu.ru/xmlui/handle/net/137231 | |
dc.description.abstract | Pharmacoepidemiology analysis of efficacy and safety of antiepileptics was carried out in children (3 months-18 years old) registered with municipal children's epilepsy services: 548 children in 2005, 718 - In 2007 and 32 - In 2011. We used remission lasting for 1 year or longer, and 3 years or longer as primary effectiveness outcomes, and total number of people with adverse effects as a safety outcome. We found no advantages of newer antiepileptics over the older ones in terms of either efficacy or safety. Long-term follow up (more than 3 years) showed higher treatment response rate in patients with childhood versus juvenile absence epilepsy. © 2012 - IOS Press and the authors. All rights reserved. | |
dc.relation.ispartofseries | International Journal of Risk and Safety in Medicine | |
dc.subject | efficacy | |
dc.subject | Pharmacoepidemiology of antiepileptics | |
dc.subject | safety | |
dc.title | Pharmacoepidemiology of antiepileptic drugs in children: Comparative analysis of efficacy and safety | |
dc.type | Article | |
dc.relation.ispartofseries-issue | 3 | |
dc.relation.ispartofseries-volume | 24 | |
dc.collection | Публикации сотрудников КФУ | |
dc.relation.startpage | 179 | |
dc.source.id | SCOPUS09246479-2012-24-3-SID84866701738 |